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A CONCEPTUAL FRAMEWORK TO APPLY DISCRETE-EVENT 
SIMULATION TO ESTIMATE THE RESOURCES NEEDED TO PERFORM A 
POPULATION BASED CANCER SCREENING PROGRAM
Comas M1, Roman R1, Mar J2, Casamitjana M1, Castells X1
1Hospital del Mar (IMAS), Barcelona, Spain, 2Hospital ‘Alto Deba’, Mondragon, Spain
OBJECTIVES: To establish a conceptual framework to estimate the resources needed 
to start a population-based cancer screening program and to estimate its long-term 
impact in terms of beneﬁt and resource use. METHODS: A conceptual model was 
deﬁned according to discrete-event simulation methodology. The conceptual model 
included, on one hand, the stages of a screening program and, on the other hand, the 
natural history of the disease. The stages of a screening program included: invitation 
of the target population, participation and screening test, conﬁrmation test(s) after a 
positive screening result, cancer diagnosis and cancer treatment. The natural history 
of the disease includes the following states: free of cancer, pre-clinical cancer phase, 
clinical (or symptomatic) cancer phase and cancer cured, including recurrences and 
death. The natural history of the disease will be modeled as time until a change of 
state, and this health states will be managed as attributes. Then, the health state will 
be taken into account through the process of screening to choose which sensitivities 
and speciﬁcities of the screening and conﬁrmatory tests should be applied. It will also 
be used to detect interval cancers. CONCLUSIONS: Using a simulation model to 
reproduce a population-based cancer screening program will allow estimating the 
amount of resources needed to implement the program. This will be applicable to 
cancers for which screening is recommended, such as colorectal cancer, but also to 
explore changes in the screening strategy such as widening of the age range for breast 
cancer screening.
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MODELLING THE UPTAKE AND DIFFUSION OF INNOVATIVE 
TECHNOLOGY: A CRITICAL AND STRATEGIC FEATURE OF BUDGET 
IMPACT ANALYSIS AND RISK-SHARING AGREEMENTS
Ethgen O, Hiligsmann M, Reginster JY
University of Liège, Liège, Belgium
The market access of innovative technology is perceptibly tensing up. Beyond cost-
effectiveness, payers increasingly scrutinize budget impact (BI) and contemplate risk-
sharing (RS) agreements. In these conditions, accurate forecasting of an innovation 
uptake and diffusion (IUD) is decisive as it determines the new technology mix evolu-
tion over time. The IUD rate is a key feature of BI modelling and cannot strategically 
be ignored in potential RS proposals in which the number of patients being given the 
innovation over time may determine RS agreement conditions. However, in the BI 
analysis and RS experiences carried out so far, it is not necessarily clear how IUD 
rates were factored in. This contribution builds upon methods developed in the tech-
nological forecasting science to predict new technology diffusion with little or no data. 
We describe the use of sigmoid growth curves (Logistic or Gompertz functions for 
instance) to account for the gradual and continuous process of an IUD within a speciﬁc 
market. Growth curves are mathematically tractable. They provide modellers and 
decision makers with remarkable ﬂexibility and transparency to run a broad range of 
adaptations, sensitivity and scenario analysis on an IUD path in BI models or RS 
proposals i.e., in simulating and comparing different market dynamics and new tech-
nology mix evolution. Bayesian updating is also described to improve curve ﬁtting in 
order to increase the accuracy of IUD forecasts as expert opinions and preliminary 
claims or sales data become available.
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REVIEWER’S CHECKLIST FOR ASSESSING THE QUALITY OF DECISION 
MODELS
Zimovetz E, Wolowacz SE
RTI Health Solutions, Manchester, UK
OBJECTIVES: The NICE Single Technology Appraisal process requires a systematic 
review of existing economic evaluations to be submitted. A critical appraisal of the 
identiﬁed studies is an important component of this review. Numerous quality assess-
ment tools have been devised to critically appraise the quality of decision models. 
However, none of these accurately reﬂect the quality criteria speciﬁed by the NICE 
Reference Case published in the updated 2008 Guide to the Methods of Technology 
Appraisal. We aimed to develop a checklist for assessing the quality of decision-analytic 
models that may be used in the context of STA submissions, and which reﬂects the 
requirements of the NICE reference case, and incorporates important elements of 
existing highly regarded tools. METHODS: A systematic review was undertaken to 
identify existing good practice guidelines and checklists for critical appraisal of health 
economics studies. We searched MEDLINE, EconLit and Health Economic Evaluations 
Database (HEED) for published guidelines and checklists, and the Internet for relevant 
grey literature, discussion papers and conference abstracts. RESULTS: We identiﬁed 
17 relevant publications. These were summarised and synthesised to determine the 
most important appraisal criteria. Based on these ﬁndings and the NICE 2008 Methods 
Guide, we propose a simple checklist which provides a means to assess the quality of 
models and the evidence underpinning them according to the Reference Case and 
evidence hierarchy speciﬁed by NICE, including identiﬁcation of evidence by systematic 
review, and selection and synthesis of outcomes data and measuring and valuing health 
effects. CONCLUSIONS: We believe the proposed checklist will provide a useful 
means for assessing the quality of health economics evaluations reﬂecting the most 
up-to-date Reference Case requirements. The checklist may be used alongside recog-
nized guidelines for critical appraisal of health economics evaluations.
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Cancer natural history models are essential when evaluating screening interventions, 
preventative interventions or changes to diagnostic pathways. Natural history models 
commonly use a state transition structure where the progression of disease is split 
into distinct disease states but it is often not possible to directly observe the state 
transition probabilities required to parameterise such a model. An existing Excel 
markov state transition model for the natural history of colorectal cancer (CRC) was 
modiﬁed and updated with recent English data. The work aimed to accurately repre-
sent the uncertainty in natural history parameters by embedding the problem in the 
framework of Bayesian inference. The Metropolis-Hastings algorithm was used to 
estimate natural history parameters by generating multiple sets of parameters from 
the posterior distribution, which is a probability distribution that is compatible with 
the observed data. Observed data included incidence categorised by age and stage, 
autopsy data on polyp prevalence, and cancer and polyp detection rates from the ﬁrst 
round of screening. The approach was implemented using Visual Basic within the 
EXCEL model and the results were subsequently examined for convergence using the 
package CODA in R 2.8.0. Outputs from the ﬁtting process were samples from the 
joint posterior distribution of the natural history parameters given the epidemiological 
data. These parameter sets are used when running PSA. The advantages of this strategy 
are that it draws efﬁciently (compared to simple Monte Carlo or Latin Hypercube) 
from a high dimensional correlated parameter space. The underlying methodology is 
well developed in the Bayesian literature. The algorithm is simple to code and could 
be run overnight on a standard desktop PC. Using this method the parameter sets are 
drawn according to their posterior probability given calibration data and thus they 
correctly summarise the residual uncertainty in the parameter space given the data 
that are available.
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WILLINGNESS TO INITIATE THERAPY AND PUBLIC HEALTH POLICY: 
AN APPLICATION TO THE STRATEGIC DEVELOPMENT OF CLINICAL 
PRACTICE GUIDELINES FOR HEPATITIS C TREATMENT
Kauf TL1, Grant WC2
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OBJECTIVES: When the course of therapy is long—particularly if treatment is expen-
sive and/or associated with signiﬁcant side effects—standards of care often include an 
early assessment of treatment effectiveness. If this “mid-therapy” assessment is posi-
tive, the patient is indicated to continue treatment; if negative, treatment is discontin-
ued. Using expected utility theory, we demonstrated previously that the availability 
and timing of such assessments can serve as a mechanism by which policymakers can 
inﬂuence patients’ treatment initiation decisions. Here, we demonstrate the interaction 
between the timing of mid-therapy assessment, willingness to initiate (WTI) therapy, 
and treatment success using an application to hepatitis C virus (HCV) treatment. 
METHODS: A simple decision tree framework was used to compare the number of 
treatment successes for a hypothetical population of 1000 patients when initial mid-
therapy assessments are conducted at 2-weeks (wks), 4-wks, and the current standard 
of care, 12-wks, with and without considerations of WTI. Test performance charac-
teristics were based on published reports. Hypothetical treatment initiation probabili-
ties were derived from the expected burden of side effects and the prior probability 
of treatment success associated with each assessment considered. RESULTS: Ignoring 
WTI, the 12-wk strategy is associated with the most expected treatment successes (471 
vs 439 and 406 for 4- and 2-wk strategies, respectively). When WTI was inversely 
proportionate to expected side effect burden, the 2-wk strategy produced more treat-
ment successes (222 vs. 190 and 141 for 4- and 12-wk strategies, respectively). If WTI 
for the 2-wk assessment exceeded 115% of the WTI for 12-wks, the 2-wk strategy 
dominated. CONCLUSIONS: The optimal timing of a mid-therapy assessment 
depends on test performance and the relative importance of side effects and treatment 
success to patients. Understanding patients’ treatment preferences can help decision 
makers design treatment guidelines that have the greatest potential to reach public 
health goals.
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A DYNAMIC MODEL TO MAXIMIZE THE HELATH BENEFITS IN 
MUTUALLY EXCLUSIVE SUSCEPTIBLE INFECTIOUS POPULATION
Chang CJ1, Wu D2, Lin YJ3, Wang PC4, Fann CS5
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To effectively control infectious diseases, great efforts have been made using empirical 
and theoretical approaches to explore the age-related characteristics of various infec-
tious diseases, such as the force of infection (FOI), the per capita rate that a susceptible 
from a certain age is infected. Among them, mathematical epidemic models have 
contributed greatly to the control of infection within population. With the relaxed 
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assumption of impractical unlimited vaccine supply, we developed a generalized 
methodology based on dynamic stochastic model utilizing the ﬂow of limited vaccine 
supply to the individuals between two mutually exclusive subgroups (e.g. different age 
groups or different risk groups) in order to examine the long term impact of different 
vaccination programs on overall health outcomes from the whole population. In 
this model, both age dependency and seasonality in FOI were explicitly considered. 
This study aims to answer two key questions: 1) what is the best vaccination strategy 
in order to attain maximal quantitative post-vaccination health beneﬁts among 
two subpopulations? and 2) how different structures of age-speciﬁc FOI’s inﬂuence 
our selection on the vaccinated population? Most of the time, one needs to have 
various parameter values in the models targeting spreading of infectious diseases in 
populations which cannot be estimated accurately. Therefore, a series of scenarios 
with different FOI’s, demographic structures, vaccine efﬁcacy and other model param-
eters were used in our simulation studies using this stochastic age-structured frame-
work. In summary, our study dynamically acquired both important biomedical and 
mathematical implications by successfully analyzing the current mass vaccination 
strategy, evaluating the effect of different prevention and intervention options, and 
served as an accurate basis for outcome research that may facilitate further cost- 
effectiveness analysis.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Patient-Reported 
Outcomes Studies
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SENSITIVITY OF 15D, EQ-5D AND SF-6D TO DIABETES 
COMPLICATIONS: THE CASE OF CORONARY HEART DISEASE
Kontodimopoulos N1, Arvanitaki-Vasilakaki E2, Chadjiapostolou Z3, Niakas D1
1Hellenic Open University, Patras, Greece, 2Ag. Varvara Health Centre, Heraklion Crete, 
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OBJECTIVES: Diabetes Mellitus (DM) patients typically suffer from comorbid condi-
tions and disease-related macro- and microvascular complications which, in conjunc-
tion to demographic, anthropometric, clinical and treatment satisfaction variables, 
have a confounding effect on health-related quality of life. Therefore, discriminative 
ability of measuring instruments is important. Three preference-based utility instru-
ments were assessed in terms of their sensitivity to a common complication of diabetes,    
i.e. coronary heart disease (CHD).    METHODS: 319 Type II DM patients (62.4% 
female, mean age 65.3) were surveyed with the 15D, EQ-5D, SF-36 and the Diabetes 
Treatment Satisfaction Questionnaire (DTSQ). Independent variables including 
gender, age, years with diabetes, BMI, HbA1c, treatment satisfaction, and existence 
of hypertension, hyperlipidaemia, COPD, arthropathy, vascular disease, diabetic foot, 
retinopathy, neuropathy and nephropathy were introduced in univariate regression 
models to identify signiﬁcant predictors of 15D, EQ-5D and SF-6D utilities. RESULTS: 
DM patients with CHD (N  107, 61.7% female, mean age 71.0) reported lower 
utilities than DM patients without: 15D, 0.740 vs. 0.841; EQ-5D, 0.627 vs. 0.756; 
SF-6D, 0.708 vs. 0.775, (P  0.001 throughout). The regression models explained 
51.1%, 39.6% and 28.0% of 15D, EQ-5D and SF-6D variance respectively. Five 
common signiﬁcant predictors (gender, age, treatment satisfaction, arthropathy and 
diabetic foot), and ﬁve others signiﬁcant in at least one model were identiﬁed, which 
were controlled for with ANCOVA. The respective results (CHD, yes vs. no) were: 
15D, 0.787 vs. 0.817, P  0.05; EQ-5D, 0.702 vs. 0.718, P  0.589; SF-6D, 0.737 
vs. 0.761, P  0.084. CONCLUSIONS: After correcting for the confounding effect of 
common diabetes variables, only the 15D produced statistically signiﬁcant HRQoL 
differences between DM patients with and without CHD, most likely due to its richer 
descriptive system. This increased sensitivity is perhaps evidence in favour of the 15D 
in diabetics suffering from CHD, but concurrently emphasizes the need for further 
testing in larger and more diverse DM patient samples.
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MEASUREMENT OF OUTPATIENT REHABILITATION OUTCOMES WITH 
EQ-5D
Reinders S1, Rasch A1, Haupts M2, Greiner W1
1University of Bielefeld, Bielefeld, Germany, 2ZAR Bielefeld GmbH, Bielefeld, Germany
OBJECTIVES: Experiences with generic health-related quality of life (HRQoL) instru-
ments in German rehabilitation facilities are very limited. The goal of this study was 
to assess the applicability of EQ-5D as part of the quality management system in a 
sample of neurological and orthopaedic patients. METHODS: The assessment was 
implemented as part of the regular optional patient satisfaction evaluation at the out-
patient rehabilitation facility in Bielefeld ( Germany). Neurological and orthopaedic 
patients were surveyed by questionnaire at the beginning (T1) and the end (T2) of 
rehabilitation treatment. The survey period was September to December of 2008. 
HRQoL was determined by the German version of EQ-5D self-report questionnaire 
(European tariff) and EQ-VAS (visual analogue scale). Wilcoxon signed-rank test was 
used for comparison of T1 and T2. RESULTS: In total, 99 patient cases (mean age 
of 52 years, 58% orthopaedic and 32% female) were included in the study. The mean 
of EQ-5D index score increased from 0.66 (SD  0.18) to 0.74 (SD  0.18) at the end 
of the rehabilitation (statistically signiﬁcant with p  0,001). Mean VAS utility value 
improved signiﬁcantly (p  0,001) from 0.57 (SD  0.21) at T1 to 0.69 (SD  0.19) 
at T2. The percentage of patients with any problems decreased for all ﬁve dimensions 
(mobility: 49% to 32%; self-care: 21% to 12%; usual activities: 66% to 48%; pain/
discomfort: 82% to 63%; anxiety/depression: 29% to 24%). CONCLUSIONS: EQ-
5D showed good sensitivity and practicability for generic measurement of rehabilita-
tion outcomes and could supplement existing compulsory quality management 
systems. A comparable and widely accepted assessment of outcome quality also would 
be of interest for payers (statutory health insurance and pension insurance), owners 
and patients.
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PATIENT COMPLETION OF EPROS: TO PHONE OR TO WEB?
Miller KL1, Jenkins E2, Silva S1, Welle J1, Collier K2, McCoy D3, Lubeck DP1
1ICON Clinical Research, San Francisco, CA, USA, 2ICON Clinical Research, Sugar Land, TX, 
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OBJECTIVES: To identify trends in patient completion patterns between two modes 
of administration for electronic patient reported outcome (ePRO) questionnaires. 
METHODSs: Retrospective review of eleven clinical research projects in which the 
patients were offered the option of completing daily questionnaires with one of two 
modes: an interactive voice response (IVR) system or a web-based response (IWR) 
system. Both systems were available to the patient at every assessment, independent 
of the mode used in prior assessment. RESULTS: In the 11 studies, data were available 
for 29,078 patients from 15 countries. On average patients completed 42 (min:1, 
max:1424) assessments during their study participation. Across the studies 2.6% of 
patients completed all assessments using only IWR and 68.5% of patients completed 
all assessments using only IVR. Of those patients using both modes (N  8408), only 
12.3% completed an IWR questionnaire more often than they completed an IVR 
questionnaire and fewer than 1% completed an equal number of IVR and IWR ques-
tionnaires. Younger patients (a25 years-old) completed more questionnaires using 
IWR (30.5% of their assessments) compared to older patients. Patients between 46 
and 65 years-old completed the fewest questionnaires using IWR (6.1% of their assess-
ments). Patients in Serbia (N  37) completed the most questionnaire using IWR 
(46.6% of their assessments). Patients in Czech Republic (N  28), Finland (N  7491), 
Italy (N  32), and New Zealand (N  7) completed the fewest questionnaires using 
IWR (5.0% of their assessments). CONCLUSIONS: Most patients completed their 
assessments using the IVR. Despite having the option, most patients did not alternate 
between modes to complete the assessments. Younger patients were more likely to 
complete the assessments using IWR. Further work is needed to evaluate whether the 
completion patterns are due to patient preference or driven by access to the chosen 
mode, particularly in some geographic regions.
PMC52
ASSESSING THE (DIS) AGREEMENT OF EQ-5D AND SF-6D ACROSS 
GROUPS WITH INCREASING SEVERITY OF CHRONIC HEART FAILURE
Kontodimopoulos N1, Argiriou M2, Theakos N2, Niakas D1
1Hellenic Open University, Patras, Greece, 2Evangelismos Hospital, Holargos Athens, Greece
OBJECTIVES: To compare EQ-5D and SF-6D utilities in chronic heart failure (CHF) 
patients with varying levels of disease severity, proxied by the Duke Activity Status 
Index (DASI). METHODS: A consecutive sample (N  251) of CHF patients undergo-
ing elective cardiac surgery were surveyed with the EQ-5D, SF-36 and the DASI, with 
the latter used to perform a uniform 5-way split of the sample according to functional 
capacity. Association and level of agreement between instruments in each severity           
group were estimated with Pearson’s r and the intraclass correlation coefﬁcient (ICC) 
respectively. Paired-samples t-test was used to identify signiﬁcant score differences, 
which were regarded as minimally important differences (MID) when exceeding 0.03. 
In a linear regression model, the DASI score was used as an anchor of disease severity 
to identify a potential “crossover” point between EQ-5D and SF-6D utilities. 
RESULTS: EQ-5D and SF-6D were in agreement and strongly correlated over the 
entire sample (ICC  0.484, P  0.001 and r  0.647, P  0.001), but correlation 
varied within the DASI-based groups. In the less severe groups (higher functional 
capacity) EQ-5D scores were signiﬁcantly higher than SF-6D scores (P  0.001) and 
differences constituted MIDs. Contrarily, in the more severe groups SF-6D was pre-
dominantly higher than EQ-5D. The regression model indicated a utility crossover 
point at 0.716 and predicted that individuals with a utility score less than this would 
score higher on the SF-6D than on the EQ-5D, and vice versa. The DASI score at 
crossover was calculated at 31.99. CONCLUSIONS: In subgroups of patients differing     
in CHF severity, mean EQ-5D and SF-6D indices differed signiﬁcantly, implying that 
the two instruments are not interchangeable and the choice of instrument for measur-
ing health-related utility can lead to variations in cost-utility analyses. Based on evi-
dence provided here, discrepancies in the instruments’ measuring range generate utility 
differences which require further investigation.
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HFS 14: A SPECIFIC QUALITY OF LIFE INSTRUMENT FOR PATIENTS 
WITH HAND-FOOT SYNDROME
Taieb C1, Sibaud V2
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Hand-foot syndrome or palmar-plantar erythrodysesthesia is a common adverse effect 
of certain chemotherapy agents, such as capecitabine or pegylated doxorubicin, where 
it is estimated to occur in 50% of cases. However, there is no speciﬁc, validated clinical 
instrument to measure its intensity and its impact on patients, apart from NCI-CTC 
grading which is relatively insensitive and is not speciﬁc. OBJECTIVES: The aim 
of this study is to develop and validate a hand-foot syndrome-speciﬁc quality of life 
scale in order to be able to measure the impact of the condition on patients and secondly 
to be able to assess the value of certain speciﬁc treatments in this indication. METHODS: 
The questionnaire was developed after conducting a series of structured interviews 
